Wei L, et al. - Using data from the UK Clinical Practice Research Datalink (CPRD), researchers examined the incidence of new-onset type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors (dutasteride or finasteride) for long-term treatment of benign prostatic hyperplasia. Men receiving dutasteride (n=8,231), finasteride (n=30,774), or tamsulosin (n=16,270) were assessed. Investigators found that the event rate per 10,000 person-years was 76.2 for dutasteride, 76.6 for finasteride, and 60.3 for tamsulosin. In men with benign prostatic hyperplasia exposed to 5α-reductase inhibitors, the risk of developing new-onset type 2 diabetes appeared to be higher than in men receiving tamsulosin, but it did not differ between men receiving dutasteride or finasteride. For men starting these drugs, additional monitoring may be required, especially in those with other risk factors for type 2 diabetes.